Tregs in ovarian cancer lesions suppress the immune response to tumor-associated antigens, which is achieved by suppressing the secretion of Interferon gamma (IFN-γ) and interleukin-2 (IL-2) by effector T cells. Here, IL2 is linked to ovarian carcinoma.